Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
11 September 2020 - 10:30PM
Business Wire
- Stephen Dilly to resign from the Sangamo board effective
September 30, 2020
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, today announced the appointment of Dr. Kenneth Hillan, an
accomplished biotechnology executive, to the Company's Board of
Directors.
"We are pleased to welcome Kenneth to the Sangamo Board of
Directors," said Sandy Macrae, Chief Executive Officer of Sangamo.
"We believe that Kenneth’s 25 years of clinical development and
executive leadership experience, as well as his current focus on
the therapeutic applications of DNA sequencing data, will provide
great benefit to Sangamo as we continue to advance our growing
pipeline of genomic medicines through clinical development.”
Since 2019, Dr. Hillan has served as Head of Therapeutics of
23andMe, the consumer genetics and research company, leading a
dedicated discovery research and therapeutic development team that
uses human genetic data to identify and pursue novel therapies for
common and rare diseases. Previously, Dr. Hillan held leadership
roles in the biotechnology industry. He served at Genentech from
1994 to 2011, where he led the medical and scientific strategies
for its Immunology, Tissue Growth and Repair drug portfolio, and
held a number of key leadership positions in research and
development, including Senior Vice President of Clinical
Development, Inflammation; Vice President of Immunology, Tissue
Growth and Repair; Vice President of Development Sciences; and Vice
President of Research Operations and Pathology. He also served as
Genentech’s Senior Vice President and Head of Clinical Development
and Product Development Strategy in Asia-Pacific for Roche in
Shanghai, China. From 2011 to 2017, he was Chief Executive Officer
of Achaogen, Inc., where he was also a member of the Board of
Directors. He has also served on the Board of Directors of
Zymeworks since February 2017, and was a member of the Board of
Directors of Relypsa from 2014 until 2016, when it was acquired by
Galenica AG.
Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery)
degree from the Faculty of Medicine at the University of Glasgow,
U.K. He is a Fellow of the Royal College of Surgeons (FRCS, Glasg),
and a Fellow of the Royal College of Pathologists (FRCPath). Dr.
Hillan has authored dozens of scientific publications and is a
named inventor on almost 50 issued patents.
Sangamo also today announced that Stephen Dilly, M.B.B.S., Ph.D.
will resign from the Board of Directors effective September 30,
2020.
“It has been a great pleasure serving as a Sangamo director for
the past decade,” said Dr. Dilly. “With a broad therapeutic
pipeline, meaningful collaborations with global biopharmaceutical
companies, and a strong balance sheet, Sangamo is well positioned
as a leader in the field of genomic medicine. I'm personally very
pleased to welcome Kenneth Hillan to the Board and am excited for
the future success of Sangamo."
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, ex vivo gene-edited cell
therapy, and in vivo genome editing and genome regulation. For more
information about Sangamo, visit www.sangamo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements relating to the potential
to develop, obtain regulatory approvals for and commercialize
therapies to treat genetic diseases and the timing thereof, the
anticipated benefits of Sangamo’s collaborations, Sangamo’s
financial resources and expectations and other statements that are
not historical fact. These statements are not guarantees of future
performance and are subject to certain risks and uncertainties that
are difficult to predict. Actual results may differ from those
projected in forward-looking statements due to risks and
uncertainties that exist in the operations and business
environments of Sangamo and its collaborators. These risks and
uncertainties are described more fully in Sangamo's Securities and
Exchange Commission filings and reports, including in Sangamo’s
Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.
Forward-looking statements contained in this announcement are made
as of this date, and Sangamo undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200911005064/en/
Investor Relations – Global McDavid
Stilwell 510-970-6000, x219 mstilwell@sangamo.com
Media Inquiries – Global Aron
Feingold 510-970-6000, x421 afeingold@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2024 to May 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From May 2023 to May 2024